Cargando…
Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/ https://www.ncbi.nlm.nih.gov/pubmed/34123391 http://dx.doi.org/10.1177/20552173211013831 |
_version_ | 1783703131881734144 |
---|---|
author | van Lierop, ZYGJ Toorop, AA Coerver, EME Willemse, EAJ Strijbis, EMM Kalkers, NF Moraal, B Barkhof, F Teunissen, CE Killestein, J van Kempen, ZLE |
author_facet | van Lierop, ZYGJ Toorop, AA Coerver, EME Willemse, EAJ Strijbis, EMM Kalkers, NF Moraal, B Barkhof, F Teunissen, CE Killestein, J van Kempen, ZLE |
author_sort | van Lierop, ZYGJ |
collection | PubMed |
description | Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch. |
format | Online Article Text |
id | pubmed-8175839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-81758392021-06-10 Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients van Lierop, ZYGJ Toorop, AA Coerver, EME Willemse, EAJ Strijbis, EMM Kalkers, NF Moraal, B Barkhof, F Teunissen, CE Killestein, J van Kempen, ZLE Mult Scler J Exp Transl Clin Brief Report Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch. SAGE Publications 2021-06-01 /pmc/articles/PMC8175839/ /pubmed/34123391 http://dx.doi.org/10.1177/20552173211013831 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Brief Report van Lierop, ZYGJ Toorop, AA Coerver, EME Willemse, EAJ Strijbis, EMM Kalkers, NF Moraal, B Barkhof, F Teunissen, CE Killestein, J van Kempen, ZLE Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title_full | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title_fullStr | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title_full_unstemmed | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title_short | Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients |
title_sort | ocrelizumab after natalizumab in jc-virus positive relapsing remitting multiple sclerosis patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175839/ https://www.ncbi.nlm.nih.gov/pubmed/34123391 http://dx.doi.org/10.1177/20552173211013831 |
work_keys_str_mv | AT vanlieropzygj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT tooropaa ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT coervereme ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT willemseeaj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT strijbisemm ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT kalkersnf ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT moraalb ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT barkhoff ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT teunissence ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT killesteinj ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients AT vankempenzle ocrelizumabafternatalizumabinjcviruspositiverelapsingremittingmultiplesclerosispatients |